FDA label 8d03bd99-9ea6-4e20-b103-6a0a1fbcdce2
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- ade6b84a-e95b-0a49-3296-f56208fdf35b
- SPL ID
- 8d03bd99-9ea6-4e20-b103-6a0a1fbcdce2
- Version
- 37
- Effective date
- 2022-04-29
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:32
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 8d03bd99-9ea6-4e20-b103-6a0a1fbcdce2 | id | |
| spl set id | ade6b84a-e95b-0a49-3296-f56208fdf35b | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Warnings and Precautions (5.4), Patient Counseling Information (17) ] For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Dosage and Administration (2.5), Warnings and Precautions (5.4) ] Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMUNEX-C does not contain sucrose. For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable. [see Warnings and Precautions (5.2) ] WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMUNEX-C does not contain sucrose. For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable. ( 5.2 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions. ( 5.1 ) Hyperproteinemia, with resultant changes in serum viscosity and electrolyte imbalances may occur in patients receiving IGIV therapy. ( 5.3 ) Aseptic Meningitis Syndrome (AMS) may occur, especially with high doses or rapid infusion. ( 5.5 ) Hemolysis, either intravascular or due to enhanced RBC sequestration, can develop subsequent to GAMUNEX-C treatments. Risk factors include high doses and non-O blood group. Closely monitor patients for hemolysis and hemolytic anemia, especially in patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. ( 5.6 ) Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). ( 5.7 ) Volume overload. ( 5.8 ) GAMUNEX-C is made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.9 ) GAMUNEX-C is not approved for subcutaneous use in ITP patients. Due to a potential risk of hematoma formation, do not administer GAMUNEX-C subcutaneously in patients with ITP. ( 5.10 ) Passive transfer of antibodies may confound serologic testing. ( 5.12 ) 5.1 Hypersensitivity Severe hypersensitivity reactions may occur with IGIV products, including GAMUNEX-C. In case of hypersensitivity, discontinue GAMUNEX-C infusion immediately and institute appropriate treatment. Have medications such as epinephrine available for immediate treatment of acute hypersensitivity reaction. GAMUNEX-C contains trace amounts of IgA (average 46 micrograms/mL). Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. It is contraindicated in IgA deficient patients with antibodies against IgA and history of hypersensitivity reaction. [see Contraindications (4) ] 5.2 Renal Failure Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur upon use of IGIV products, especially those containing sucrose.( 7,8 ) GAMUNEX-C does not contain sucrose. Ensure that patients are not volume depleted prior to the initiation of the infusion of GAMUNEX-C. Periodic monitoring of renal function and urine output is particularly important in patients judged to have a potential increased risk for developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN)/serum creatinine, prior to the initial infusion of GAMUNEX-C and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of GAMUNEX-C. [see Patient Counseling Information (17) ] For patients judged to be at risk for developing renal dysfunction, including patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, administer GAMUNEX-C at the minimum infusion rate practicable [less than 8 mg/kg/min (0.08 mL/kg/min)]. [see Dosage and Administration (2.5) ] 5.3 Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving IGIV treatment, including GAMUNEX-C. It is clinically critical to distinguish true hyponatremia from a pseudohyponatremia that is associated with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity and a possible predisposition to thrombosis.( 9 ) 5.4 Thrombosis Thrombosis may occur following treatment with immune globulin products, including GAMUNEX-C.( 10-12 ) Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Boxed Warning, Dosage and Administration (2.5), Patient Counseling Information (17) ] 5.5 Aseptic Meningitis Syndrome (AMS) AMS may occur infrequently with IGIV treatment, including GAMUNEX-C. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following IGIV treatment. AMS is characterized by the following symptoms and signs: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. Cerebrospinal fluid (CSF) studies are frequently positive with pleocytosis up to several thousand cells per cu mm, predominantly from the granulocytic series, and with elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such symptoms and signs including CSF studies, to rule out other causes of meningitis. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV. 5.6 Hemolysis GAMUNEX-C may contain blood group antibodies which may act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin reaction and hemolysis.( 13-16 ) Delayed hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration, and acute hemolysis consistent with intravascular hemolysis, has been reported. [see Adverse Reactions (6) ] The following risk factors may be related to the development of hemolysis: high doses (e.g., ≥ 2 grams/kg, single administration or divided over several days) and non-O blood group.( 17 ) Underlying inflammatory state in an individual patient may increase the risk of hemolysis, but its role is uncertain.( 18 ) Closely monitor patients for clinical signs and symptoms of hemolysis [see Warnings and Precautions (5.11) ] , particularly patients with risk factors noted above and those with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 hours and again 7 to 10 days post infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform additional confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis. 5.7 Transfusion-related Acute Lung Injury (TRALI) Noncardiogenic pulmonary edema may occur in patients following treatment with IGIV products, including GAMUNEX-C.( 19 ) TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically occur within 1 to 6 hours after treatment. Monitor patients for pulmonary adverse reactions. [see Patient Counseling Information (17) ] If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.8 Volume Overload The high dose regimen (1 g/kg x 1-2 days) is not recommended for individuals with expanded fluid volumes or where fluid volume may be a concern. 5.9 Transmission of Infectious Agents Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD have ever been identified for GAMUNEX-C. ALL infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Grifols Therapeutics LLC [1-800-520-2807]. 5.10 Hematoma Formation Do not administer GAMUNEX-C subcutaneously in patients with ITP because of the risk of hematoma formation. 5.11 Monitoring: Laboratory Tests Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of GAMUNEX-C and at appropriate intervals thereafter. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis. If signs and/or symptoms of hemolysis are present after an infusion of GAMUNEX-C, perform appropriate laboratory testing for confirmation. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and patient’s serum. 5.12 Interference with Laboratory Tests After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs) test.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table ID="SPLSERV-DDF05E19-E5E4-9777-DA3F-B3BE66C515AE" border="0" cellpadding="4" cellspacing="0" width="101%"><caption>Table 5: Most Frequent Adverse Reactions (≥ 5% of subjects) by Subject and Infusion in the SC Phase</caption><colgroup><col/><col/><col/><col/><col/></colgroup><tbody><tr><td align="center" rowspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"> Adverse Reaction </td><td align="center" colspan="2" styleCode="Lrule Rrule Toprule" valign="bottom"> Adult, Adolescent (Study 060001) </td><td align="center" colspan="2" styleCode="Lrule Rrule Toprule" valign="bottom"> Child, Adolescent (Study T5004-401) </td></tr><tr><td align="center" styleCode="Lrule Rrule Toprule" valign="bottom"> No. of Subjects n=32 (%) </td><td align="center" styleCode="Lrule Rrule Toprule" valign="bottom"> No. of Adverse Reactions (Rate<footnote ID="SPLSERV-C203575A-DD01-94CB-8C52-87B928D063A1">For each trial, rate is calculated by the total number of events divided by the number of infusions received (725 for the adult and adolescent trial and 121 for the children / adolescent trial).</footnote>) </td><td align="center" styleCode="Lrule Rrule Toprule" valign="bottom"> No. of Subjects n=11 (%) </td><td align="center" styleCode="Lrule Rrule Toprule" valign="bottom"> No. of Adverse Reactions (Rate<footnoteRef IDREF="SPLSERV-C203575A-DD01-94CB-8C52-87B928D063A1"/>) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule"> Local Infusion Site Reaction<footnote ID="SPLSERV-5E821767-137D-EA42-4187-4C907B85FCEA">All local infusion site reactions were <content styleCode="italics">a priori</content> considered drug-related</footnote><sup>,</sup><footnote ID="SPLSERV-CC672A98-340A-8A27-B56F-E09965812226">At each level of summation (Preferred Term), infusion site reactions are counted only once if they occur at the same infusion visit.</footnote> </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 24 (75.0%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 427 (0.59) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 11 (100%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 61 (0.50) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule"> Fatigue </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 5 (15.6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 6 (0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Headache</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 4 (12.5%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 25 (0.03) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Upper respiratory tract infection </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 4 (12.5%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 5 (0.01) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01) </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Arthralgia </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 3 (9.4%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 6 (0.01) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Diarrhea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 3 (9.4%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 6 (0.01) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Nausea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 3 (9.4%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 4 (0.01) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Sinusitis</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 3 (9.4%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 4 (0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Abdominal pain</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (3.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (0.02)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Abdominal pain upper</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Autoimmune thyroiditis</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Drug hypersensitivity</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Influenza</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Oropharyngeal pain</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Skin chapped</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Viral upper respiratory tract infection</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Wheezing</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (3.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (9.1%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 1 (0.01)</td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Bronchitis</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Depression</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Dermatitis allergic</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Erythema</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Migraine</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Myalgia</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Pyrexia</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr><tr><td styleCode="Botrule Lrule Rrule Toprule">Viral infection</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (6.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 2 (<0.01)</td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule"> 0 </td></tr></tbody></table>
adverse reactions table
<table ID="SPLSERV-A71A7221-1661-54D5-B579-F16834BD756D" cellpadding="4" width="80%"><caption>Table 6: Adverse Reactions Occurring in ≥ 5% of Subjects</caption><colgroup><col align="left" width="33.23%"/><col align="left" width="33.4%"/><col align="left" width="33.36%"/></colgroup><tbody><tr><td align="center" styleCode="Botrule Lrule Rrule" valign="bottom">Adverse Reaction</td><td align="center" styleCode="Botrule Rrule">GAMUNEX<sup>®</sup>-C No. of subjects: 48 Number (percentage of all subjects)</td><td align="center" styleCode="Botrule Rrule">GAMIMUNE<sup>®</sup> N, 10% No. of subjects: 49 Number (percentage of all subjects)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Headache</td><td align="center" styleCode="Botrule Rrule">25 (52.1%)</td><td align="center" styleCode="Botrule Rrule">26 (53.1%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Vomiting</td><td align="center" styleCode="Botrule Rrule">6 (12.5%)</td><td align="center" styleCode="Botrule Rrule">8 (16.3%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Ecchymosis</td><td align="center" styleCode="Botrule Rrule">7 (14.6%)</td><td align="center" styleCode="Botrule Rrule">2 (4.1%)<content ID="_com_1" language="JavaScript"/></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Fever</td><td align="center" styleCode="Botrule Rrule">6 (12.5%)</td><td align="center" styleCode="Botrule Rrule">6 (12.2%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Nausea</td><td align="center" styleCode="Botrule Rrule">6 (12.5%)</td><td align="center" styleCode="Botrule Rrule">5 (10.2%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Rash</td><td align="center" styleCode="Botrule Rrule">4 (8.3%)</td><td align="center" styleCode="Botrule Rrule">0 </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Abdominal pain</td><td align="center" styleCode="Botrule Rrule">3 (6.3%)</td><td align="center" styleCode="Botrule Rrule">3 (6.1%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Back pain</td><td align="center" styleCode="Botrule Rrule">3 (6.3%)</td><td align="center" styleCode="Botrule Rrule">2 (4.1%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Dyspepsia</td><td align="center" styleCode="Botrule Rrule">3 (6.3%)</td><td align="center" styleCode="Botrule Rrule">0</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Asthenia</td><td align="center" styleCode="Botrule Rrule">2 (4.2%)</td><td align="center" styleCode="Botrule Rrule">3 (6.1%)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Dizziness</td><td align="center" styleCode="Botrule Rrule">2 (4.2%)</td><td align="center" styleCode="Botrule Rrule">3 (6.1%)</td></tr></tbody></table>
adverse reactions table
<table ID="SPLSERV-E4CFABF1-046C-E57F-7EA1-B7D6303BB39F" cellpadding="4" width="80%"><caption>Table 7: Reasons for Discontinuation Due to Adverse Events </caption><colgroup><col align="left" width="17.23%"/><col align="left" width="16.23%"/><col align="left" width="33.4%"/><col align="left" width="33.36%"/></colgroup><tbody><tr><td align="center" colspan="2" styleCode="Botrule Lrule Rrule" valign="bottom">Number of Subjects</td><td align="center" styleCode="Botrule Rrule">Number of Subjects Discontinued due to Adverse Events</td><td align="center" styleCode="Botrule Rrule" valign="bottom">Adverse Event</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top">GAMUNEX<sup>®</sup>-C</td><td align="center" styleCode="Botrule Rrule" valign="top">113</td><td align="center" styleCode="Botrule Rrule" valign="top">3 (2.7%)</td><td align="center" styleCode="Botrule Rrule" valign="top">Urticaria, Dyspnea, Bronchopneumonia</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule" valign="top">Placebo</td><td align="center" styleCode="Botrule Rrule" valign="top">95</td><td align="center" styleCode="Botrule Rrule" valign="top">2 (2.1%)</td><td align="center" styleCode="Botrule Rrule" valign="top"> Cerebrovascular Accident, Deep Vein Thrombosis </td></tr></tbody></table>
adverse reactions table
<table ID="SPLSERV-3EE04473-B156-65CA-6C9F-84C416462A6C" width="100%"><caption>Table 8: Adverse Reactions Occurring in ≥ 5% of Subjects</caption><colgroup><col align="left" width="28%"/><col align="left" width="12%"/><col align="left" width="12%"/><col align="left" width="12%"/><col align="left" width="12%"/><col align="left" width="12%"/><col align="left" width="12%"/></colgroup><tbody><tr><td align="center" styleCode="Lrule Rrule"> </td><td align="center" colspan="3" styleCode="Botrule Lrule Rrule">GAMUNEX<sup>®</sup>-C No. of subjects: 113</td><td align="center" colspan="3" styleCode="Botrule Rrule">Placebo No. of subjects: 95</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule" valign="bottom">MedDRA Preferred Term<footnote ID="SPLSERV-B0AFD933-4F6B-A5D3-D8E6-0B473BDC3012">Reported in ≥ 5% of subjects in any treatment group.</footnote></td><td align="center" styleCode="Botrule Rrule"><paragraph>No. of Subjects (%)</paragraph></td><td align="center" styleCode="Botrule Rrule">No. of Adverse Reactions</td><td align="center" styleCode="Botrule Rrule">Incidence density<footnote ID="SPLSERV-C3B687A6-B676-95EA-8087-18427C9A08EE">Calculated by the total number of adverse reactions divided by the number of infusions received (1096 for GAMUNEX-C and 575 for Placebo).</footnote></td><td align="center" styleCode="Botrule Lrule Rrule"><paragraph>No. of Subjects (%)</paragraph></td><td align="center" styleCode="Botrule Rrule">No. of Adverse Reactions</td><td align="center" styleCode="Botrule Rrule">Incidence density<footnoteRef IDREF="SPLSERV-C3B687A6-B676-95EA-8087-18427C9A08EE"/></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Headache </td><td align="center" styleCode="Botrule Rrule">35 (31.0%)</td><td align="center" styleCode="Botrule Rrule">50</td><td align="center" styleCode="Botrule Rrule">0.046</td><td align="center" styleCode="Botrule Rrule">7 (7.4%)</td><td align="center" styleCode="Botrule Rrule">9</td><td align="center" styleCode="Botrule Rrule">0.016</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Pyrexia</td><td align="center" styleCode="Botrule Rrule">15 (13.3%)</td><td align="center" styleCode="Botrule Rrule">27</td><td align="center" styleCode="Botrule Rrule">0.025</td><td align="center" styleCode="Botrule Rrule">0</td><td align="center" styleCode="Botrule Rrule">0</td><td align="center" styleCode="Botrule Rrule"> </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Hypertension</td><td align="center" styleCode="Botrule Rrule">10 (8.8%)</td><td align="center" styleCode="Botrule Rrule">19</td><td align="center" styleCode="Botrule Rrule">0.017</td><td align="center" styleCode="Botrule Rrule">3 (3.2%)</td><td align="center" styleCode="Botrule Rrule">3</td><td align="center" styleCode="Botrule Rrule">0.005</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Chills</td><td align="center" styleCode="Botrule Rrule">9 (8.0%) </td><td align="center" styleCode="Botrule Rrule">10</td><td align="center" styleCode="Botrule Rrule">0.009</td><td align="center" styleCode="Botrule Rrule">0</td><td align="center" styleCode="Botrule Rrule">0</td><td align="center" styleCode="Botrule Rrule"> </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Nausea</td><td align="center" styleCode="Botrule Rrule">7 (6.2%)</td><td align="center" styleCode="Botrule Rrule">9</td><td align="center" styleCode="Botrule Rrule">0.008</td><td align="center" styleCode="Botrule Rrule">3 (3.2%)</td><td align="center" styleCode="Botrule Rrule">3</td><td align="center" styleCode="Botrule Rrule">0.005</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Rash</td><td align="center" styleCode="Botrule Rrule">7 (6.2%)</td><td align="center" styleCode="Botrule Rrule">10</td><td align="center" styleCode="Botrule Rrule">0.009</td><td align="center" styleCode="Botrule Rrule">1 (1.1%)</td><td align="center" styleCode="Botrule Rrule">1</td><td align="center" styleCode="Botrule Rrule">0.002</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Arthralgia</td><td align="center" styleCode="Botrule Rrule">6 (5.3%)</td><td align="center" styleCode="Botrule Rrule">7</td><td align="center" styleCode="Botrule Rrule">0.006</td><td align="center" styleCode="Botrule Rrule">0</td><td align="center" styleCode="Botrule Rrule">0</td><td align="center" styleCode="Botrule Rrule"> </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule">Asthenia</td><td align="center" styleCode="Botrule Rrule">6 (5.3%)</td><td align="center" styleCode="Botrule Rrule">6</td><td align="center" styleCode="Botrule Rrule">0.005</td><td align="center" styleCode="Botrule Rrule">1 (1.1%)</td><td align="center" styleCode="Botrule Rrule">2</td><td align="center" styleCode="Botrule Rrule">0.003</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.